Robot | Path | Permission |
GoogleBot | / | ✔ |
BingBot | / | ✔ |
BaiduSpider | / | ✔ |
YandexBot | / | ✔ |
User-agent: * Disallow: |
Title | Home | Kartos |
Description | Mapping a Path to Breakthrough Kartos Therapeutics is a clinical stage biopharmaceutical company with an investigational MDM2 inhibitor, navtemadlin (KRT-232), |
Keywords | N/A |
WebSite | kartosthera.com |
Host IP | 173.231.240.47 |
Location | United States |
Site | Rank |
US$10,719,878
Last updated: 2023-05-09 06:35:53
kartosthera.com has Semrush global rank of 987,353. kartosthera.com has an estimated worth of US$ 10,719,878, based on its estimated Ads revenue. kartosthera.com receives approximately 1,236,909 unique visitors each day. Its web server is located in United States, with IP address 173.231.240.47. According to SiteAdvisor, kartosthera.com is safe to visit. |
Purchase/Sale Value | US$10,719,878 |
Daily Ads Revenue | US$9,896 |
Monthly Ads Revenue | US$296,859 |
Yearly Ads Revenue | US$3,562,298 |
Daily Unique Visitors | 82,461 |
Note: All traffic and earnings values are estimates. |
Host | Type | TTL | Data |
kartosthera.com. | A | 3600 | IP: 173.231.240.47 |
kartosthera.com. | NS | 7200 | NS Record: ns63.worldnic.com. |
kartosthera.com. | NS | 7200 | NS Record: ns64.worldnic.com. |
kartosthera.com. | MX | 3600 | MX Record: 10 us-smtp-inbound-1.mimecast.com. |
kartosthera.com. | MX | 3600 | MX Record: 10 us-smtp-inbound-2.mimecast.com. |
kartosthera.com. | TXT | 3600 | TXT Record: 0ed1fe018aaa60e2c40b6b4905ba4008ea7d3d3524 |
kartosthera.com. | TXT | 3600 | TXT Record: ZOOM_verify_7zGfg5q4QnCb0tI9biB0qg |
kartosthera.com. | TXT | 3600 | TXT Record: docusign=63092d3e-551d-4d45-82da-acb980d33002 |
kartosthera.com. | TXT | 3600 | TXT Record: v=spf1 include:us._netblocks.mimecast.com include:mail.zendesk.com include:spf.protection.outlook.com -all |
kartosthera.com. | TXT | 3600 | TXT Record: geadcfnm62icmjkbcmkf15nd9v |
kartosthera.com. | TXT | 3600 | TXT Record: MS=ms62029283 |
Science Research Advocacy About Contact Jobs Mapping a Path to Breakthrough Therapies Dedicated to the development of novel, targeted therapeutics that meaningfully improve the lives of patients with cancer Discover the science MDM2 KRT-232 p53 The MDM2-p53 interaction represents a compelling therapeutic target with potential to provide a new treatment option for patients across selected solid tumors and hematological malignancies Navtemadlin (KRT-232) A novel, potent, and selective oral MDM2 inhibitor Active Clinical Studies KRT-232 MDM2 KARTOS THERAPEUTICS is a clinical stage biopharmaceutical company with an investigational MDM2 inhibitor, navtemadlin (KRT-232) 275 Shoreline Drive, Suite 300 Redwood City, CA 94065 +1 650.542.0130 info@kartosthera.com © 2023 Kartos Therapeutics Inc Science Navtemadlin (KRT-232) Research Clinical Trials Expanded Access Advocacy About Overview Leadership Contact Jobs Terms of Use Privacy Policy Cookie Policy © 2023 Kartos Therapeutics, Inc. All rights |
HTTP/1.1 406 Not Acceptable Date: Sun, 31 Oct 2021 10:12:57 GMT Server: Apache Content-Type: text/html; charset=iso-8859-1 |
Domain Name: KARTOSTHERA.COM Registry Domain ID: 2218159166_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.networksolutions.com Registrar URL: http://networksolutions.com Updated Date: 2021-01-26T16:30:06Z Creation Date: 2018-01-24T21:07:05Z Registry Expiry Date: 2027-01-24T21:07:05Z Registrar: Network Solutions, LLC Registrar IANA ID: 2 Registrar Abuse Contact Email: abuse@web.com Registrar Abuse Contact Phone: +1.8003337680 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: NS63.WORLDNIC.COM Name Server: NS64.WORLDNIC.COM DNSSEC: unsigned >>> Last update of whois database: 2021-09-18T20:06:38Z <<< |